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The most widely used antimalarial drugs belong to the quinoline
family. Their mode of action has not been characterized at the
molecular level in vivo. We report the in vivo mode of action of a
bromo analog of the drug chloroquine in rapidly frozen Plasmodium
falciparum-infected red blood cells. The Plasmodium parasite digests
hemoglobin, liberating the heme as a byproduct, toxic to the parasite.
It is detoxified by crystallization into inert hemozoin within the par-
asitic digestive vacuole. By mapping such infected red blood cells with
nondestructive X-ray microscopy, we observe that bromoquine caps
hemozoin crystals. The measured crystal surface coverage is sufficient
to inhibit further hemozoin crystal growth, thereby sabotaging heme
detoxification. Moreover, we find that bromoquine accumulates in
the digestive vacuole, reaching submillimolar concentration, 1,000-
fold more than that of the drug in the culture medium. Such a dra-
matic increase in bromoquine concentration enhances the drug’s
efficiency in depriving heme from docking onto the hemozoin crystal
surface. Based on direct observation of bromoquine distribution in
the digestive vacuole and at its membrane surface, we deduce that
the excess bromoquine forms a complex with the remaining heme
deprived from crystallization. This complex is driven toward the di-
gestive vacuole membrane, increasing the chances of membrane
puncture and spillage of heme into the interior of the parasite.
malaria | cryo X-ray microscopy | drug tracking |
inhibition of crystallization | hemozoin
Human malaria, a reemerging infectious disease, is caused byseveral types of protozoan parasites of the genus Plasmodium.
It has been one of the primary concerns to humanity for centuries
and is now extended to more than 40% of the world’s population.
Our focus will be on the most virulent of such species, Plasmodium
falciparum. Increasing geographical spread of the species resistant
to current drug treatments is a cause of serious concern (1–3).
Characterizing how current antimalarial drugs work at the mo-
lecular level is a key for intelligent design of improved antimalarial
drugs needed to combat the disease.
As part of its life cycle the Plasmodium parasite invades a red
blood cell, where it catabolizes hemoglobin to grow and multiply.
The hemoglobin, on digestion in the parasitic digestive vacuole, re-
leases iron-containing heme molecules, which are toxic to the par-
asite. The heme is rendered inert by crystallization into hemozoin.
We have recently shown that the parasite stores large quantities of
hemoglobin in its digestive vacuole (4). For the parasite to survive,
the rate of heme liberation via hemoglobin digestion must not
exceed the rate of hemozoin crystallization. Hindering this step
would lead to buildup of the toxic heme within the parasite (5, 6).
Among proposed hypotheses, the quinoline-family drugs are
believed to damage the parasite by the following steps: 1) via
quinoline capping the growing hemozoin crystals, thereby retard-
ing deposition of heme onto the crystal surface (7–10), and 2)
complexing with free heme in the lumen of the digestive vacuole
(11–14), although this process should be secondary in terms of
inhibiting crystal growth (9). The net result in both hypotheses is
damage imparted to the parasite by heme released from hemo-
globin but unable to crystallize (15, 16).
Thus, to establish the mechanism of antimalarial action by
quinoline drugs, it was imperative to determine the crystal
structure of hemozoin. A breakthrough was achieved by Pagola
et al. (17) nearly 20 y ago characterizing the crystal structure of
synthetic hemozoin (see SI Appendix, section 1 and Fig. S1),
which is composed of heme dimers. Based on this crystal struc-
ture it became possible to characterize the faces of hemozoin (SI
Appendix, Fig. S1B) and so devise a model of quinoline drug
binding to the {100}, {001}, and {011} faces, as was proposed by
Weissbucht and Leiserowitz (7) and Buller et al. (18). Later,
Kapishnikov and Leiserowitz, in an article by Biot and coworkers
(8), provided an improved model of chloroquine-type binding to
the hemozoin {100} face, which involves an acid–base interaction
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between a quinoline molecule and 2 accessible heme propionic
acid groups spanning 2 unit cells on the well-expressed {100} face.
However, to date, all growth inhibition studies have been done on
synthetic hemozoin.
Various approaches were employed to investigate whether and
how such drugs inhibit hemozoin crystallization (9, 18, 19). In
vitro studies monitored crystallization of synthetic hemozoin in
the presence of drug molecules, whose affinity to the crystal
surface and inhibition of crystallization was tested, but in media
different from that of the parasitic digestive vacuole (9, 20, 21).
A more direct mode of investigation involved localization of the
drug ferroquine within the malaria parasite itself (22), albeit in a
dried red blood cell.
In order to validate the proposed mechanisms of action of
antimalarial quinoline drugs we raised the following questions.
What is the concentration of the drug in the digestive vacuole
of the parasite? Does the drug indeed bind to the hemozoin
crystal faces and persist at these crystal surfaces in vivo? If so,
would the crystal surface coverage by the drug be sufficient to
inhibit regular heme dimer adsorption onto the crystal faces?
Finally, can we detect or envisage binding of the drug to
free heme?
With these considerations in mind, we undertook a correla-
tive X-ray microscopy study to establish the mode of action of
established drugs like chloroquine via its localization within hy-
drated malaria parasites in their native, albeit rapidly frozen,
environment. We provide evidence that both mechanisms take
place and argue that the interaction is sufficient to disrupt heme
detoxification. We used bromoquine (BrQ), an analog of chlo-
roquine (cf. Fig. 1A), to take advantage of the identifiable X-ray
fluorescence signal of the bromine substituent, assuming that
BrQ’s molecular biological properties do not differ significantly
from that of chloroquine (23, 24). We found that BrQ accumulates
at high concentrations in the digestive vacuole, thousandfold
exceeding that in the culture medium. Within the digestive vacu-
ole, BrQ caps the hemozoin crystal surface. Such a coverage,
defined as the fraction of surface docking sites capped by BrQ and
found to range between 4% and 15%, is sufficient to hinder the
deposition of oncoming heme molecules. We also observed that
BrQ covers hemozoin crystals isolated from the parasites to the
same extent as in the digestive vacuole. This suggests a persistent
binding of BrQ to the crystal surface. We deduce that BrQ forms a
complex with isolated heme, which accumulates at the digestive
vacuole membrane, possibly spreading to other parasitic mem-
branes, leading to their disruption.
Based on these in vivo observations, we present in the closing
words of this paper a model of the antimalarial mode of action
by BrQ and, by extension, that of related quinolines.
Results
To verify the first hypothesis that quinoline drugs cap hemozoin
crystals, we colocalize the iron (Fe) signal of hemozoin crystals
with the bromine (Br) signal of BrQ. In order to assess the
efficiency of hemozoin growth inhibition by capping with BrQ
we measure the BrQ coverage on the surface of hemozoin
crystals.
To provide evidence of strong attachment of BrQ to the
hemozoin crystal surface we compare BrQ coverage of crystals
within the digestive vacuole with those isolated from the para-
sites. We find a similar coverage in both cases, suggesting strong
interaction between BrQ and the hemozoin crystal surface.
To validate that our calculations do not include background Br
signal from culture medium, we analyze the Br distribution in
BrQ-treated and BrQ-free samples. We find that background Br
originating from bovine serum used to culture the parasites does
not significantly enter the digestive vacuole.
We identify an increased concentration of BrQ at the
membrane of the digestive vacuole. This can be explained by BrQ
Fig. 1. (A) Bromoquine molecule, BrQ, where Br takes the place of chlorine of the original drug chloroquine (see BrQ Synthesis andMethods for synthesis of BrQ). (B)
Soft X-ray projection through parasite 1 along the same beam direction as in X-ray fluorescence maps shown inD and E. For parasite 1 the parasite membrane and the
digestive vacuole (DV) are delineated by green and orange dots, respectively. Clusters of hemozoin (Hz) crystals are denoted by blue arrowheads. (C) Full segmentation
of soft X-ray tomogram of the infected red blood cell (iRBC) labeled “C”with different compartments rendered in artificial colors. The 2 parasites that share the same
red blood cell are colored green and blue and labeled parasite 1 and parasite 2, respectively. (D) X-ray fluorescence map of Fe in iRBC labeled “C” containing both
parasites. Parasite 1 is delineated in accordance with the delineation in C. (E) X-ray fluorescence map of Br in the same infected red blood cell with parasite 1 de-
lineated in the same way as in D. The similarity between the fluorescence maps of Fe and Br clearly demonstrates the affinity of BrQ molecules for attachment to the
Hz crystals. The intensity scale factor IFe/IBr ∼ 272 (see main text) with an estimated uncertainty of 15%. The corresponding BrQ coverage is (7 ± 2)%.
Kapishnikov et al. PNAS | November 12, 2019 | vol. 116 | no. 46 | 22947
CH
EM
IS
TR
Y
BI
O
PH
YS
IC
S
A
N
D
CO
M
PU
TA
TI
O
N
A
L
BI
O
LO
G
Y
D
ow
nl
oa
de
d 
at
 C
O
PE
NH
AG
EN
 U
NI
VE
RS
IT
Y 
LI
BR
AR
Y 
on
 N
ov
em
be
r 2
9,
 2
01
9 
complexation with free heme (see Discussion), thereby validating
the second hypothesis that quinoline drugs interact with free heme.
Finally, to verify immediate availability of BrQ at the site of
hemozoin nucleation and growth we measure concentration of
BrQ within the digestive vacuole but not attached to hemozoin
crystals. We find it accumulates in the digestive vacuole at a
thousandfold higher concentration than in the culture medium,
confirming previously reported estimates (25–27).
BrQ Caps Hemozoin Crystals in Infected Red Blood Cells. A red blood
cell, which happened to be invaded by 2 parasites (Fig. 1), was
treated with BrQ drug 30 h after infection. The cell was non-
destructively imaged by soft X-ray cryotomography with the
photon energy within the so-called water window range in which
oxygen atoms are practically transparent and carbon atoms are
heavily absorbing. This generates strong contrast between lipid,
cytoplasm, and hemozoin crystals (Fig. 1B), enabling direct
tomographic mapping of cellular structure within entire parasites
without the need for staining.
A sample with infected red blood cells, frozen in 20-μm-thick
ice, was mapped by soft X-ray cryotomography. From the tomo-
graphic data it was possible to render a complete 3-dimensional
(3D) picture of an infected red blood cell, shown in Fig. 1C in
artificial colors.
The cell was subsequently mapped by X-ray fluorescence
cryomicroscopy. This involves raster scanning with a 30-nm-
diameter hard X-ray beam, which causes fluorescent X-rays to be
emitted uniformly in all directions, with an energy spectrum reflecting
the element distribution in the irradiated volume. The scan pro-
vides a distribution map for each atomic element, but here we
consider only the contributions of Fe and Br as shown in Fig. 1 D
and E. The similarity between the Fe map in Fig. 1D and the
calculated soft X-ray projection in Fig. 1B enables an unambiguous
association between Fe and Br distribution and structure of
parasite 1, including hemozoin crystals and its digestive vacuole.
Clearly, large Br concentrations are located precisely in the same
regions as the large Fe concentrations of the hemozoin crystals.
Similar overlap has been observed in every BrQ-treated parasite,
while no such overlap has been observed in any of the BrQ-free
parasites. In total, 7 BrQ-treated and 9 BrQ-free parasites were
mapped by X-ray fluorescence cryomicroscopy.
BrQ Caps One-Tenth of Hemozoin Surface Docking Sites within
Parasites. First, we assume there is no occlusion of the BrQ in-
to hemozoin crystals since no direct evidence was found for the
existence of quinine or chloroquine within synthetic hemozoin
grown in their presence (21). Hence, BrQ is always located at the
hemozoin crystal surface.
Let Nsurf be the number of unit cells on the crystal surfaces at
which a fraction Ccvrg is covered by BrQ molecules. The number of
BrQ molecules at the hemozoin surface is Ccvrg·(Nsurf/2) because 1
BrQ molecule will bind to 2 adjacent surface unit cells on the
{100}, {011}, and {001} faces (see Introduction and SI Appendix,
section 1). We shall, for convenience, assume that the BrQ binds
equally well on the different faces since {h,k,l} face assignment
was not possible due to the limited spatial resolution.
Let Nbulk define the total number of unit cells in the bulk of the
hemozoin crystals. The number of Fe atoms constituting the
hemozoin crystals is 2·Nbulk, because 1 unit cell of hemozoin con-
tains 2 Fe atoms (cf. SI Appendix, Fig. S1A).
The ratio of the number of BrQ molecules to Fe atoms is then
NBrQ
NFe
=
Ccvrg

Nsurf

2

2Nbulk
=Ccvrg ·
Nsurf
Nbulk
·
1
4
.
At this point, we take into account that the measured X-
ray fluorescence intensity I per atom of Br is 5.4 times
higher than that for Fe, as detailed in SI Appendix, section 2.
Therefore,
NBrQ
NFe
=
1
5.4
·
IBr
IFe
=Ccvrg ·
Nsurf
Nbulk
·
1
4
.
From this equation we derive the surface coverage:
Ccvrg =
4
5.4
·
IBr
IFe
·
Nbulk
Nsurf
.
An estimate of the fluorescence signal ratio, IBr=IFe =
40=ð8× 103Þ= 1 : 200, can be obtained by inspection of the ver-
tical color scales of the 2 maps (Fig. 1 D and E). A more precise
measure is obtained by summing up the intensities in the Fe map
(Fig. 1D) within the pixel area of hemozoin crystals and in the
same pixel area in the Br map (Fig. 1E) with a constant back-
ground subtracted. The result is a ratio of 1:272.
What remains to be assessed is the ratio Nbulk=Nsurf for all of
the hemozoin crystals in the digestive vacuole. This was done by
measuring the volume and surface area of the cluster of hemozoin
crystals using soft X-ray tomography datasets, as detailed in SI Ap-
pendix, section 4.1, resulting in the value Nbulk=Nsurf = 108=3.9 · 106
for parasite 1.
We thus estimate the resulting fractional coverage Ccvrg to be
Ccvrg = 45.4 ·
IBr
IFe
· NbulkNsurf =
4
5.4 ·
1
272 ·
108
3.9 · 106 = 0.07, that is, 7 ± 3% of avail-
able BrQ docking sites (see SI Appendix, section 4.1 for the estimate
of the error in surface coverage).
For this doubly invaded red blood cell (iRBC labeled C, Fig. 1)
the BrQ drug was introduced into the parasite culture at a
concentration of 150 nM, which is in the range of the therapeutic
dose of chloroquine (28).
In another infected red blood cell (iRBC labeled A in Fig. 4),
the concentration at which BrQ was introduced into the culture
was 40 nM, in keeping with previous measurements reported in
the literature (22). Based on the same analytical procedure, the
coverage onto hemozoin by BrQ was measured to be ∼10 ± 4%.
This extent is nearly the same as that for iRBC C, even though the
drug was introduced at an almost 4 times lower concentration.
Isolated Hemozoin Crystals outside Red Blood Cells Are Capped with
Bromoquine. The Fe X-ray fluorescence map shown in Fig. 2
reveals several isolated hemozoin crystals outside infected red
blood cells. Regarding the origin of these ex vivo crystals, we
present 2 scenarios. The crystals may have originated from rupture
of previous-generation parasites in the process of release of their
daughter parasites at the end of the parasitic asexual red blood
cell cycle (29). It is also possible that these crystals were released
from those few parasites that were destroyed by BrQ. These ex
vivo crystals are marked Hz1, Hz2, and so on in Fig. 2A. A close-
up view of Hz1 is shown both as Fe and Br maps in Fig. 2B,
providing prima facie evidence that the BrQ molecule has
a distinct affinity to be absorbed onto the surface of hemozoin
crystals.
Below we present a determination of BrQ coverage on crystal
Hz1, making once again use of the equation
Ccvrg =
4
5.4
·
IBr
IFe
·
Nbulk
Nsurf
.
We have also analyzed 7 other samples of isolated hemozoin
crystals (shown in SI Appendix, Fig. S3) and incorporate all 8 mea-
surements (SI Appendix, Table S1 in SI Appendix, section 5) for
estimating the average coverage. This estimate is along the same
lines as for the analysis within an infected red blood cell (discussed
above). However, all isolated crystals were outside the focal plane
for soft X-ray tomography measurements, so the determination of
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surface area SHz of each crystal was carried out solely by an analysis
of its X-ray fluorescence maps, as detailed in SI Appendix, section
4.2. Briefly, the number of unit cells in the bulk of the crystal,Nbulk,
was derived from the number of Fe atoms comprising the crystal
measured by X-ray fluorescence with the knowledge that the unit
cell of hemozoin consists of 2 Fe atoms. The number of surface
unit cells Nsurf was derived from the crystal surface divided by the
weighted average area of surface unit cells. For crystal Hz1 the
ratio Nbulk=Nsurf was determined to be equal 1.2 · 106=1.5 · 105. See
SI Appendix, section 4.2 for the detailed calculation.
The average X-ray fluorescence intensities of Br and Fe across
Hz1 are, IBr = 15 and IFe = 700, respectively (Fig. 2B). The
coverage of BrQ on crystal Hz1 is then
Ccvrg =
4
5.4
·
IBr
IFe
·
Nbulk
Nsurf
=
4
5.4
·
15
700
·
1.2 · 106
1.5 · 105
≈ 0.12.
The same analysis for all 8 isolated crystals yielded an average
BrQ coverage of around 0.070 ± 0.035, that is, 7 ± 3.5%. Further
experiments with a higher spatial resolution are required to de-
termine the different affinities of BrQ to the {100} and the {010}
faces of hemozoin (8).
Bromine from Bovine Serum Does Not Cap Hemozoin Crystals. We
have identified 2 sources of Br atoms in the examined samples.
One is the BrQ drug introduced at the ∼100 nM level. The second
source is background Br originating from bovine serum used for
culturing the malaria parasites, reportedly present in the form of
2-octyl γ-bromoacetoacetate (30, 31). Measured concentrations of
the background Br range up to 4 μM. As shown below, we have
been able to effectively separate the total Br signal arising from
BrQ and the serum and establish unambiguously that only BrQ
decorates hemozoin crystals and the digestive vacuole membrane.
Inspection of the Fe map and the Br map in Fig. 1 shows
clearly that Br tends to accumulate on hemozoin crystals, both
for parasites 1 and 2. There is also some lower Br signal in the
parasites but outside their hemozoin clusters. This signal may arise
from the drug BrQ as well as from Br in the serum. In order to
distinguish between these 2 sources of Br, we analyze Br distri-
bution in BrQ-treated and the BrQ-free parasites.
We analyzed 7 BrQ-treated and 9 BrQ-free parasites. In BrQ-
treated parasites, we identify distinct areas of Br overlaying
hemozoin (Figs. 1 and 3A). In BrQ-free parasites there is no such
overlay (Fig. 3B). However, the difference in overlay is not al-
ways as clear to the naked eye as shown in other examples given
in SI Appendix, Fig. S6. We have taken up this challenge by
quantifying the extent of overlap of Br with hemozoin in BrQ-
treated and BrQ-free parasites. This extent is given in form of an
overlap parameter OBr,Hz. When there is no overlap OBr,Hz = 0.
In case there is an overlap OBr,Hz > 0. The overlap parameter for
several BrQ-treated and BrQ-free parasites is plotted in Fig. 3C.
The exact definition and calculation of the overlap parameter
are presented in SI Appendix, section 9.
For 9 BrQ-free cells OBr,Hz varied between −0.2 and 0.2, the
olive-colored dots in Fig. 3C. In the cell shown in Fig. 1, where
the overlap is obvious to the eye, the overlap parameter came
out to be OBr,Hz > 1. This is recorded in Fig. 3C by 2 red dots
marked “C” belonging to the 2 parasites residing in this doubly
invaded cell. Therefore, the figure shows quantitatively that, al-
though not always as visible as in Fig. 1, there is indeed overlap
between Br signal and Hz crystals in BrQ-treated cells, while no
such overlap occurs in the BrQ-free samples.
The average overlap parameter in the BrQ-treated cells is
0.57 ± 0.40. In the BrQ-free cells it is 0.09 ± 0.12.
BrQ Accumulates at the Membrane of the Digestive Vacuole. In most
of the parasites examined, an elevated Br X-ray fluorescence
signal appears to decorate the parasitic membranes, including the
parasitic nucleus. Br also appears to decorate the digestive vacuole
but only in BrQ-treated parasites. In order to examine whether it is
the membranes that are decorated by Br, a Br distribution image
was simulated by virtually placing Br atoms along the 3D positions
of the membranes of the digestive vacuole, the nucleus, and the
parasite as shown in Fig. 4. In order to accomplish this task, we
have made a crude estimate of Br membrane coverage by summing
the Br atoms along the periphery of the digestive vacuole membrane
Fig. 2. (A) Fe X-ray fluorescence map showing a cluster of Hz crystals grown in an infected red blood cell (iRBC) labeled E prior to introduction of the BrQ
drug, as well as several free-floating Hz crystals labeled Hz1, Hz2, and so on outside the red blood cell. There is a weak (light bluish) Fe signal in the red blood
cell originating from hemoglobin still not digested by the parasite. (B) Magnification of the Hz1 map showing Fe signal (Left) and bromine (Br) signal (Right).
(C) The theoretical growth form of Hz crystals (18) emphasizing that the {100} and {010} are the prevailing faces. (D) Section through the Fe map shown in B,
along the crystal needle axis (in orange) and transverse to it (in green).
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(seen in Fig. 4 A and C) and dividing this value by measured area of
the selected membrane at the corresponding coordinates. This
resulted in a Br coverage of 5 × 103 atoms per square micrometer of
the membrane.
The 3D coordinates of the parasite membranes were obtained
from soft X-ray tomographic reconstruction of the same cell
whose lipid membranes are well-resolved. The striking resem-
blance of the simulated (Fig. 4D) and the measured Br distribu-
tion (Fig. 4C) indicates that the signal comes from a relatively
uniform distribution of the Br atoms along the membranes.
BrQ capping of hemozoin crystals can also be confirmed by
comparing the measured Br map (Fig. 4C) and 2 simulated Br
distributions: with and without BrQ capping hemozoin crystals
(Fig. 4 D and E, respectively). Other parasites with similar trend
in Br distribution are shown in Fig. 3 and SI Appendix, Fig. S6.
A closer inspection of parasite membranes seen in Br maps in
Fig. 3 and SI Appendix, Fig. S6 reveals that the digestive vacuole
membrane is decorated by Br only in BrQ-treated parasites with
the digestive vacuole membrane well-delineated in 4 parasites
occupying iRBCs A, B, D, and E. We therefore conclude that the
Br signal at hemozoin crystals and the digestive vacuole mem-
brane indeed originates from BrQ and not from Br found in
bovine serum.
Similar observations were made by Dubar et al. (22), who
reported the presence of the quinoline drug, ferroquine, close to
the digestive vacuole membrane of a Plasmodium-infected red
blood cell imaged by transmission electron microscopy, and by
Woodland et al. (32), who used visible light fluorescence mi-
croscopy to locate covalently labeled chloroquine at the digestive
vacuole membrane and other parasitic membranes.
BrQ Reaches High Concentrations in the Digestive Vacuole. We
measured concentration of Br in the lumen of the parasitic di-
gestive vacuole in BrQ-treated parasites by counting Br atoms in
Fig. 3. Overlap between Fe and Br distribution in BrQ-treated samples and BrQ-free samples. (A) Fe and Br X-ray fluorescence maps of an infected red blood
cell (iRBC D) treated by BrQ. DV denotes the digestive vacuole and Hz the hemozoin crystals. (B) Fe and Br signals in a BrQ-free infected red blood cell (iRBC K).
(C) Overlap parameter, OBr,Hz, between hemozoin position and Br fluorescence signal in 7 BrQ-treated and 9 BrQ-free samples. Each dot represents a
measurement within an individual parasite carrying the name of its host iRBC. iRBCs named A through K are shown in SI Appendix, Fig. S6; others are labeled
with a hash mark. iRBCs C and A are shown in Figs. 1 and 2, respectively. The overlap parameter = 0 if there is no overlap between Br and hemozoin and >0 if
there is such an overlap.
Fig. 4. Surface rendering, measured and simulated X-ray fluorescence maps of a BrQ-treated infected red blood cell (iRBC) labeled A. (A) Surface rendering
of a soft X-ray tomography segmentation. (B) Measured Fe X-ray fluorescence map. (C) Measured Br X-ray fluorescence map. (D) Simulated Br X-ray fluo-
rescence map. Br atoms were evenly distributed over the surface of the digestive vacuole (DV) membrane, the parasite nucleus, and the parasite membrane
with the density of 5 × 103 atoms per square micrometer, and on the surface of hemozoin (Hz) crystals with a density corresponding to 10% BrQ surface
coverage. (E) Same simulation as D but without Br at the surface of Hz crystals.
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4 infected red blood cells (iRBCs A, B, D, and E shown in SI
Appendix, Fig. S6) in regions within their digestive vacuoles
outside hemozoin crystals. The number of Br atoms was divided
by the corresponding volume within each of the digestive vacu-
oles yielding Br concentrations. This concentration reaches a
magnitude similar to what has been reported for chloroquine
(25–27). We found that BrQ accumulated in the digestive vac-
uoles, reaching concentrations of 150 ± 50 μM, even though BrQ
was introduced into the culture medium at the concentrations as
low as 40 nM and 150 nM. The concentration of BrQ in the
digestive vacuole was measured in a more direct manner than
previously reported for chloroquine, albeit in fewer cells.
Discussion
We investigate the mode of quinoline-family drug action within
Plasmodium-infected red blood cells. We have conducted a
quantitative measurement of in vivo distribution of the antima-
larial drug BrQ within fully hydrated, rapidly frozen, P. falciparum-
infected red blood cells in the trophozoite stage. These cells are
not subject to any artifact deriving from dehydration, staining,
chemical fixation, or sectioning and thus provide the closest sce-
nario to an unperturbed biological picture of the drug intervention
in the infected red blood cells. Native distribution of chemical
elements was measured in the vitrified infected cells at specific
time points of parasitic development and drug action.
An elevated presence of bromine atoms was detected within
the Plasmodium parasitized cells. No bromine signal above
background level (set by the concentration of Br atoms in the
bovine serum) was detected either within the cytosol compart-
ment of the red blood cell or at its membrane. This observation
suggests that once the quinoline molecule reaches the Plasmodium
parasite, having penetrated the red blood cell, it stays therein.
Importantly, BrQ accumulates in the digestive vacuole, reaching
concentrations as high as 150 μM, that is, thousandfold higher
than the concentration introduced into the culture medium. It is
by virtue of the fact that the digestive vacuole is an acidic or-
ganelle with pH in the range of 4.5 to 4.9 (33) that BrQ, being a
weak base, accumulates therein at high concentrations, as has
been earlier suggested for chloroquine (18, 27).
Here we have established that BrQ accumulates at the hemozoin
crystal surface and at the digestive vacuole membrane, and
possibly at other membranes of the parasite. The crystal sur-
face coverage, measured as a fraction of its surface binding sites
blocked by the drug, is between 4% and 15% analyzed for 2
parasites and 8 isolated crystals. We note the presence of BrQ in
the lumen of the digestive vacuoles in regions outside the hemozoin
crystals at submillimolar concentrations (discussed above), enough
to cover an additional 7% of the hemozoin crystals. This result
suggests that the BrQ coverage on hemozoin had reached a
maximum. BrQ was also found capping large hemozoin crystals
floating in the culture medium outside infected red blood cells in
which they have been formed. The measured BrQ coverage at
these hemozoin surfaces is also within the range of 4% and 15%.
This observation confirms strong affinity of BrQ to the hemozoin
crystal surface.
Based on computational analysis (8, 18), we conclude that the
preferred affinity of BrQ toward the hemozoin crystal surface is
likely due to a stereospecific match and attraction between the
quinoline molecule and the large {100} side faces and fast-
growing {011} and {001} end faces. An essentially homogeneous
10% surface coverage by BrQ should certainly inhibit crystal
growth since any oncoming heme dimer will be within 2 unit cell
distances of an adsorbed BrQ molecule, and so susceptible to
forces unfavorable for docking at a regular surface lattice site on
the hemozoin crystal. Such an inhibition would lead to accu-
mulation of the chemically aggressive heme liberated from he-
moglobin, resulting in poisoning of the parasite.
We now address the question of the ability of BrQ to smother
the hemozoin crystalline surface in the early stages of parasitic
development, say a couple of hours after hemozoin crystals begin
to form. In a 2-fL digestive vacuole of a young trophozoite (SI
Appendix, Table S1; electron microscopy data in ref. 34), as-
suming that half the digestive vacuole volume would be freely
occupied by BrQ at 150 μM concentration, the amount of BrQ
would be ∼90,000 molecules. This amount would be sufficient to
block 11% of hemozoin crystal surface developed at this stage
(SI Appendix, section 11), implying, all in all, that BrQ would be
efficient all the way from the onset of parasitic production of
hemozoin crystals.
We now address the observation of an elevated BrQ presence
at the membrane of the digestive vacuole. This membrane is
clearly visible in soft X-ray tomographic images. In the BrQ-
treated parasite the membrane is highlighted in X-ray fluores-
cence maps of Br, indicating the presence of BrQ molecules. The
presence of background Br in parasites precludes analysis of BrQ
molecule distribution in other parasitic membranes. Nonethe-
less, in a recent study by Woodland et al. (32), chloroquine
molecules covalently labeled for light fluorescence microscopy
were detected also in other parasitic membranes, but not on red
blood cell membranes, which is in accordance with our obser-
vations. We note that in their work little signal from the labeled
molecule over hemozoin-rich area was detected, which is possi-
bly due to signal absorption by the crystals. It is debatable
whether the water-soluble drug would, by itself, tend to accu-
mulate at the lipid membranes. However, the drug molecule has
high affinity to complex with free heme in the aqueous medium
of the digestive vacuole with the acidic pH. Indeed, the possi-
bility of quinoline drug complexation with free heme has been
proposed in the literature (7–16). The affinity to water of this
complex is presumably higher than that of free heme but lower
than that of BrQ alone. We therefore rationalize that this
complex would be driven toward and accumulate at the lipid
membrane of the digestive vacuole. Supporting this hypothesis is a
report of chloroquine–hemin complex association with lipid
membranes observed in vitro (35–37). A prolonged exposure of
the digestive vacuole membrane to an increased presence of BrQ–
heme complex might lead to intercalation of the heme or the
complex with the membrane, leading to its local puncture and
spread of the toxic heme into the interior of the parasite (36, 37).
We found that BrQ reaches the same concentrations in the
digestive vacuole of chloroquine-resistant strain FCR3 as in the
BrQ-sensitive 3D7 strain and displays similar distribution in both
strains (SI Appendix, Fig. S6). We interpret this observation as
either lack of resistance to BrQ by the FCR3 strain or a resis-
tance mechanism other than the previously suggested reduction
of BrQ concentration in the digestive vacuole (1). Further in-
vestigation needs to be conducted to clarify this point.
Conclusion
Using a correlative X-ray microscopy approach, we have iden-
tified that in vivo BrQ—the bromo analog of chloroquine—
covers a substantial part of available docking sites at the surface
of hemozoin crystals formed in the digestive vacuole of the
Plasmodium parasites. Quantification of quinoline-type molecule
in vivo coverage of hemozoin crystals in fully hydrated cells was
achieved. This coverage was as high as 10 ± 4%, enough to
prevent oncoming heme docking onto the crystals. The drug was
found in abundance in the digestive vacuole. We have provided
evidence, albeit indirect, that the drug complexes with free heme,
given that the drug binds to the hemozoin surface. This complex
accumulates at the membrane of the digestive vacuole, as ob-
served by bromine X-ray fluorescence signal, and possibly
spreads to other membranes. In other words, both hypotheses
mentioned in the Introduction take place in vivo. This model
can be generalized to quinoline drugs, such as quinine, which can
Kapishnikov et al. PNAS | November 12, 2019 | vol. 116 | no. 46 | 22951
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stereospecifically bind to the {100}, {011}, and {001} faces of
hemozoin.
Last, but not least, the approach described here would be
applicable to test whether other antimalarial drugs, such as the
widely used artemisinin as an in vivo adduct with heme (38), will
bind to hemozoin crystals (21, 39), provided an appropriate atom
detectable by X-ray fluorescence can be attached to the drug.
BrQ Synthesis and Methods
Synthesis of BrQ and the NMR spectrum of the synthesized
product are given in SI Appendix, section 12.
Malaria parasite culture and strain verification are described
in SI Appendix, section 13. Tight synchronization resulting in 30- to
32-h-postinvasion parasites is detailed in SI Appendix, section 14.
IC50 (concentration that inhibits parasite growth by 50%) values
of chloroquine and BrQ for chloroquine-sensitive (3D7) and
chloroquine-resistant (FCR3) strains and the measurement pro-
cedure are given in SI Appendix, section 15.
Preparation of vitrified samples for cryo X-ray microscopy is
described in SI Appendix, section 16. Cryo X-ray fluorescence and
soft X-ray cryotomography instruments are described in SI Ap-
pendix, section 17. Software used in data analysis and presentation
is described in SI Appendix, section 18.
ACKNOWLEDGMENTS. S.K. acknowledges Carlsberg Foundation for a post-
doctoral fellowship and S.K., L.L., and J.A.-N. acknowledge the Ib Henriksen
Foundation for support. Yang Yang (University of Copenhagen) and J.L.
thank Novo Nordisk Foundation and the Department of Chemistry, University
of Copenhagen for financial support related to the synthesis of bromoquine.
S.K. and J.A.-N. thank the Carlsberg Foundation and DanScatt for facilitating
meetings and travel to the synchrotron light source. S.K.’s accommodation
expenses at Helmholtz-Zentrum Berlin were covered by CALIPSOplus. Core
Facility for IntegratedMicroscopy at theUniversity of Copenhagen is acknowledged
for access to the high-pressure freezer. We acknowledge Helmholtz-Zentrum
Berlin, ALBA synchrotron light source, and European Synchrotron Research
Facility for the allocation of synchrotron radiation beamtime at U41-PGM1-
XM, MISTRAL, and ID16A (experiments ls2704, ls2843) beamlines, respectively.
We thank James G. McNally (Helmholtz-Zentrum Berlin), Orn Almarsson
(Moderna Therapeutics), Joel Sussman (Weizmann Institute of Science), and
Poul Nissen (University of Aarhus) for critical reading of the manuscript.
1. P. S. Callaghan, P. D. Roepe, “The biochemistry of quinoline antimalarial drug
resistance” in Handbook of Antimicrobial Resistance, M. Gotte, A. Berghuis,
G. Matlashewski, M. Wainberg, D. Sheppard, S. N. York, N. York, Eds. (Springer, New
York, 2014), pp. 1–20.
2. R. M. Fairhurst, A. M. Dondorp, Artemisinin-resistant Plasmodium falciparum malaria.
Microbiol. Spectr. 4 (2016).
3. A. Maxmen, How to defuse malaria’s ticking time bomb. Nature 559, 458–465 (2018).
4. S. Kapishnikov et al., Unraveling heme detoxification in the malaria parasite by in situ
correlative X-ray fluorescence microscopy and soft X-ray tomography. Sci. Rep. 7, 7610
(2017).
5. P. G. Bray, S. A. Ward, P. M. O’Neill, Quinolines and artemisinin: Chemistry, biology
and history. Curr. Top. Microbiol. Immunol. 295, 3–38 (2005).
6. A. P. Gorka, A. de Dios, P. D. Roepe, Quinoline drug-heme interactions and implica-
tions for antimalarial cytostatic versus cytocidal activities. J. Med. Chem. 56, 5231–
5246 (2013).
7. I. Weissbuch, L. Leiserowitz, Interplay between malaria, crystalline hemozoin forma-
tion, and antimalarial drug action and design. Chem. Rev. 108, 4899–4914 (2008).
8. F. Dubar et al., The antimalarial ferroquine: Role of the metal and intramolecular
hydrogen bond in activity and resistance. ACS Chem. Biol. 6, 275–287 (2011).
9. K. N. Olafson, T. Q. Nguyen, J. D. Rimer, P. G. Vekilov, Antimalarials inhibit hematin
crystallization by unique drug-surface site interactions. Proc. Natl. Acad. Sci. U.S.A.
114, 7531–7536 (2017).
10. S.-M. Fitzroy et al., The effects of quinoline and non-quinoline inhibitors on the ki-
netics of lipid-mediated β-hematin crystallization. Langmuir 33, 7529–7537 (2017).
11. P. A. Adams, P. A. M. Berman, T. J. Egan, P. J. Marsh, J. Silver, The iron environment in
heme and heme-antimalarial complexes of pharmacological interest. J. Inorg. Biochem.
63, 69–77 (1996).
12. T. J. Egan, W. W. Mavuso, D. C. Ross, H. M. Marques, Thermodynamic factors controlling
the interaction of quinoline antimalarial drugs with ferriprotoporphyrin IX. J. Inorg.
Biochem. 68, 137–145 (1997).
13. D. C. Warhurst, The quinine-haemin interaction and its relationship to antimalarial
activity. Biochem. Pharmacol. 30, 3323–3327 (1981).
14. E. Hempelmann, Hemozoin biocrystallization in Plasmodium falciparum and the an-
timalarial activity of crystallization inhibitors. Parasitol. Res. 100, 671–676 (2007).
15. J. H. Ch’ng, K. Liew, A. S. P. Goh, E. Sidhartha, K. S. W. Tan, Drug-induced per-
meabilization of parasite’s digestive vacuole is a key trigger of programmed cell
death in Plasmodium falciparum. Cell Death Dis. 2, e216 (2011).
16. F. Dubar et al., Deciphering the resistance-counteracting functions of ferroquine in
Plasmodium falciparum-infected erythrocytes. ACS Med. Chem. Lett. 3, 480–483
(2012).
17. S. Pagola, P. W. Stephens, D. S. Bohle, A. D. Kosar, S. K. Madsen, The structure of
malaria pigment β-haematin. Nature 404, 307–310 (2000).
18. R. Buller, M. L. Peterson, O. Almarsson, L. Leiserowitz, Quinoline binding site on malaria
pigment crystal: A rational pathway for antimalarial drug design. Cryst. Growth Des. 2,
553–562 (2002).
19. D. J. Sullivan, Jr, I. Y. Gluzman, D. G. Russell, D. E. Goldberg, On the molecular
mechanism of chloroquine’s antimalarial action. Proc. Natl. Acad. Sci. U.S.A. 93,
11865–11870 (1996).
20. J. Gildenhuys, T. le Roex, T. J. Egan, K. A. de Villiers, The single crystal X-ray structure
of β-hematin DMSO solvate grown in the presence of chloroquine, a β-hematin
growth-rate inhibitor. J. Am. Chem. Soc. 135, 1037–1047 (2013).
21. I. Solomonov et al., Crystal nucleation, growth, and morphology of the synthetic
malaria pigment beta-hematin and the effect thereon by quinoline additives: The
malaria pigment as a target of various antimalarial drugs. J. Am. Chem. Soc. 129,
2615–2627 (2007).
22. F. Dubar et al., In situ nanochemical imaging of label-free drugs: A case study of
antimalarials in Plasmodium falciparum-infected erythrocytes. Chem. Commun.
(Camb.) 48, 910–912 (2012).
23. S. R. Vippagunta et al., Structural specificity of chloroquine-hematin binding related
to inhibition of hematin polymerization and parasite growth. J. Med. Chem. 42,
4630–4639 (1999).
24. D. De, F. M. Krogstad, L. D. Byers, D. J. Krogstad, Structure-activity relationships for
antiplasmodial activity among 7-substituted 4-aminoquinolines. J. Med. Chem. 41,
4918–4926 (1998).
25. S. R. Hawley et al., Relationship between antimalarial drug activity, accumulation,
and inhibition of heme polymerization in Plasmodium falciparum in vitro. Anti-
microb. Agents Chemother. 42, 682–686 (1998).
26. T. G. Geary, J. B. Jensen, H. Ginsburg, Uptake of [3H]chloroquine by drug-sensitive and
-resistant strains of the human malaria parasite Plasmodium falciparum. Biochem.
Pharmacol. 35, 3805–3812 (1986).
27. A. Yayon, Z. I. Cabantchik, H. Ginsburg, Susceptibility of human malaria parasites to
chloroquine is pH dependent. Proc. Natl. Acad. Sci. U.S.A. 82, 2784–2788 (1985).
28. D. K. Molina, Postmortem hydroxychloroquine concentrations in nontoxic cases. Am.
J. Forensic Med. Pathol. 33, 41–42 (2012).
29. Y. Michalakis, F. Renaud, Malaria: Evolution in vector control. Nature 462, 298–300
(2009).
30. N. Bryan, K. D. Andrews, M. J. Loughran, N. P. Rhodes, J. A. Hunt, Elucidating the
contribution of the elemental composition of fetal calf serum to antigenic expression
of primary human umbilical-vein endothelial cells in vitro. Biosci. Rep. 31, 199–210
(2011).
31. M. P. Patricelli, J. E. Patterson, D. L. Boger, B. F. Cravatt, An endogenous sleep-
inducing compound is a novel competitive inhibitor of fatty acid amide hydrolase.
Bioorg. Med. Chem. Lett. 8, 613–618 (1998).
32. J. G. Woodland, R. Hunter, P. J. Smith, T. J. Egan, Chemical proteomics and super-
resolution imaging reveal that chloroquine interacts with Plasmodium falciparum
multidrug resistance-associated protein and lipids. ACS Chem. Biol. 13, 2939–2948
(2018).
33. R. Hayward, K. J. Saliba, K. Kirk, The pH of the digestive vacuole of Plasmodium
falciparum is not associated with chloroquine resistance. J. Cell Sci. 119, 1016–1025
(2006).
34. S. Kapishnikov et al., Oriented nucleation of hemozoin at the digestive vacuole
membrane in Plasmodium falciparum. Proc. Natl. Acad. Sci. U.S.A. 109, 11188–11193
(2012).
35. H. Ginsburg, O. Famin, J. Zhang, M. Krugliak, Inhibition of glutathione-dependent
degradation of heme by chloroquine and amodiaquine as a possible basis for their
antimalarial mode of action. Biochem. Pharmacol. 56, 1305–1313 (1998).
36. H. Ginsburg, R. A. Demel, Interactions of hemin, antimalarial drugs and hemin-
antimalarial complexes with phospholipid monolayers. Chem. Phys. Lipids 35,
331–347 (1984).
37. H. Ginsburg, R. A. Demel, The effect of ferriprotoporphyrin IX and chloroquine on
phospholipid monolayers and the possible implications to antimalarial activity. Bio-
chim. Biophys. Acta 732, 316–319 (1983).
38. A. Robert, Y. Coppel, B. Meunier, Alkylation of heme by the antimalarial drug artemi-
sinin. Chem. Commun. (Camb.) 414–415 (2002).
39. Y. L. Hong, Y. Z. Yang, S. R. Meshnick, The interaction of artemisinin with malarial
hemozoin. Mol. Biochem. Parasitol. 63, 121–128 (1994).
22952 | www.pnas.org/cgi/doi/10.1073/pnas.1910123116 Kapishnikov et al.
D
ow
nl
oa
de
d 
at
 C
O
PE
NH
AG
EN
 U
NI
VE
RS
IT
Y 
LI
BR
AR
Y 
on
 N
ov
em
be
r 2
9,
 2
01
9 
